WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

16 January 2018

 Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (EN NL )

 

 

15 January 2018

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease (ENNLFRES)

UPCOMING EVENTS

  • INVESTORS AND PARTNERING
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
41.82 USD
Change (%):
0.47 (1.14%)
BRU
1.72 EUR
Change (%):
0.00 (0.23%)


ABOUT US

CORPORATE VIDEO

CORPORATE PRESENTATION


FACT SHEET